http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
CASE REPORT : A Case of Ectopic Adrenocorticotropic Hormone Syndrome in Small Cell Lung Cancer
( Chaiho Jeong ),( Jinhee Lee ),( Seongyul Ryu ),( Hwa Young Lee ),( Ah Young Shin ),( Ju Sang Kim ),( Joong Hyun Ahn ),( Hye Seon Kang ) 대한결핵 및 호흡기학회 2015 Tuberculosis and Respiratory Diseases Vol.78 No.4
Small cell lung cancer (SCLC), which originated from neuroendocrine tissue, can develop into paraneoplastic endocrine syndromes, such as Cushing syndrome, because of an inappropriate secretion of ectopic adrenocorticotropic hormone (ACTH). This paraneoplastic syndrome is known to be a poor prognostic factor in SCLC. The reason for poor survival may be because of a higher risk of infection associated with hypercortisolemia. Therefore, early detection and appropriate treatment for this syndrome is necessary. But the diagnosis is challenging and the source of ACTH production can be difficult to identify. We report a 69-year-old male patient who had severe hypokalemia, metabolic alkalosis, and hypertension as manifestations of an ACTH-secreting small cell carcinoma of the lung. He was treated with ketoconazole and spironolactone to control the ACTH dependent Cushing syndrome. He survived for 15 months after chemotherapy, which is unusual considering the poor outcome of the ectopic ATH syndrome associated with SCLC.
The efficacy of denosumab in Korean male patients with osteoporosis
Chaiho Jeong,Jeonghoon Ha,Jinyoung Kim,Yejee Lim,Mee Kyoung Kim,Hyuk-Sang Kwon,Ki-Ho Song,Moo-Il Kang,Ki-Hyun Baek 대한내과학회 2022 The Korean Journal of Internal Medicine Vol.37 No.5
Background/Aims: Despite the prominence of denosumab as the number one prescribed anti-osteoporosis drug in Korea, the effects of denosumab in male osteoporosis patients were not researched sufficiently. Moreover, concerns on rebound vertebral fractures associated with poor denosumab adherence exist. Methods: We retrospectively evaluated 147 Korean male osteoporosis patients treated with denosumab. After 12 months of treatment, 60 patients were lost during follow-up, and eight were excluded due to missing data. Out of the initial 147 patients, 79 were considered eligible for the analysis of the efficacy of denosumab. 54 patients were initially drug-naïve, and 25 had previously received bisphosphonate therapy. Results: In 54 drug-naïve patients, significant increases in bone mineral density (BMD) were observed in all measurement sites: 5.2% ± 3.7% in the lumbar spine, 2.3% ± 2.8% in the femoral neck, and 1.9% ± 2.8% in the total hip (p < 0.01, respectively). Trabecular bone score showed an increase of 0.5% ± 5.8% in drug-naïve patients. Likewise, in 25 patients with previous bisphosphonate treatment, increase in BMD were observed as well: 4.8% ± 3.5% in the lumbar spine, 1.4% ± 3.6% in the femoral neck, and 0.8% ± 2.1% in the total hip (p < 0.01, p = 0.06, p = 0.06, respectively). Significant declines of –55.1% ± 31.8% in C-terminal telopeptide of type 1 collagen (CTX), and –62.9% ± 21.3% in total procollagen 1 N-terminal propeptide (P1NP), in drug-naïve patients; and –37.7% ± 41.5%, in CTX and –55.4% ± 30.1%, in P1NP in patients with previous bisphosphonate treatment were exhibited after 12 months of treatment. The adherence rates of the second and third dosing schedules were 79.9% and 56.8%, respectively. Conclusions: Our study indicates that denosumab is effective in increasing BMD in Korean osteoporosis males regardless of prior bisphosphonate treatment.
The Effect of Denosumab on Bone Mass in Super Elderly Patients
Chaiho Jeong,하정훈 대한골대사학회 2020 대한골대사학회지 Vol.27 No.2
Background: Denosumab is a potent antiresorptive drug leading to significant reduction in the risk of vertebral and non-vertebral fractures in postmenopausal osteoporosis. The effect of denosumab in super-elderly patients lacks data to date and few literature has proven the efficacy to this specific group. The purpose of this study was to determine the effectiveness and safety of denosumab in the super-elderly. Methods: We retrospectively evaluated 60 patients older than 80 with osteoporosis treated with denosumab. Patients were treated with denosumab every 6 months for 12 months 2017 to 2020. The primary endpoint was defined by the changes in bone mineral density (BMD) of 3 measurement sites: the lumbar spine, femoral neck, and total hip. Changes in bone turnover markers, serum calcium, serum phosphate, and 25-hydroxy-vitamin D were also observed. Results: All 60 patients were female, and the mean age was 83.9±3.1, from age 80 to 94. After 12 months of denosumab treatment, significant increases in BMD were observed; 3.02±2.74% for the lumbar spine (P=0.000), 3.10±6.90% for the femoral neck (P=0.005), and 2.89±5.80% for the total hip (P=0.002) The bone turnover marker C-terminal telopeptide of type I collagen and osteocalcin significantly declined after 12 months of treatment (-34.8±45.9%; P=0.002 and –35.5±38.9%; P=0.004 respectively). Symptomatic hypocalcemia and serious adverse drug reactions that required drug discontinuation were not observed during treatment. Conclusions: Denosumab is thought to be an anti-osteoporotic medication that is sufficiently effective and safe even for the super-elderly.
Roles of Follicle-Stimulating Hormone on Bone Metabolism in Late Postmenopausal Women
Chaiho Jeong,Jinyoung Kim,Yejee Lim,Jeonghoon Ha,Mee-Kyoung Kim,Hyuk-Sang Kwon,Ki-Ho Song,Moo-Il Kang,Ki-Hyun Baek 대한골대사학회 2022 대한골대사학회지 Vol.29 No.3
Background: The effects of elevated follicle-stimulating hormone (FSH) levels on physi- ological changes in the bone remain unclear. This study aimed to clarify the association between FSH concentrations and bone mineral density (BMD) and bone turnover mark- ers (BTM) in late postmenopausal women. Methods: A total of 169 Korean women were enrolled. The participants’ ages ranged from 60 to 84 years (mean age, 69.0±5.1) and reported a mean duration of 19.4±6.6 years since menopause (YSM). The participants showed an average body mass index (BMI) of 24.4±2.8 kg/m2. Age, YSM, estradiol, tes- tosterone, and BMI were confounders in the Pearson's partial correlation. A test for trends across the quartiles of FSH levels was performed for each variable. Results: The mean FSH and estradiol concentrations were 61.5 IU/L and 2.9 pg/mL, respectively. Serum FSH concentration was not significantly associated with BMD (lumbar, r = 0.09, P = 0.30; total hip, r = 0.00, P = 0.96; and femoral neck, r = 0.05, P = 0.62). BTM across the FSH quartiles did not show any trend association (bone-specific alkaline phosphate, P = 0.31; cross- linked C-terminal telopeptide of type I collagen, P = 0.90). Instead, FSH levels were nega- tively correlated with BMI (r = -0.34, P = 0.00). In the multivariate regression model ad- justed for age, testosterone, and estradiol, only BMI showed a negative value across the FSH quartiles (β coefficient -0.11, P = 0.00). Conclusions: This study identified that high FSH concentrations were not associated with bone loss or high bone turnover in women in the late postmenopausal period.
Scattering theory of space-time non-commutative abelian gauge field theory
Chaiho Rim,Jae Hyung Yee 한국물리학회 2005 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.46 No.4
The unitary S-matrix for space-time non-commutative quantum electrodynamics is constructed using the time ordering which is needed in the presence of derivative interactions. Based on this S-matrix, we formulate the perturbation theory and present the Feynman rule. We then apply this perturbation analysis to the Compton scattering process to the lowest order and check the gauge invariance of the scattering amplitude at this order.
A Case of Ectopic Adrenocorticotropic Hormone Syndrome in Small Cell Lung Cancer
Jeong, Chaiho,Lee, Jinhee,Ryu, Seongyul,Lee, Hwa Young,Shin, Ah Young,Kim, Ju Sang,Ahn, Joong Hyun,Kang, Hye Seon The Korean Academy of Tuberculosis and Respiratory 2015 Tuberculosis and Respiratory Diseases Vol.78 No.4
Small cell lung cancer (SCLC), which originated from neuroendocrine tissue, can develop into paraneoplastic endocrine syndromes, such as Cushing syndrome, because of an inappropriate secretion of ectopic adrenocorticotropic hormone (ACTH). This paraneoplastic syndrome is known to be a poor prognostic factor in SCLC. The reason for poor survival may be because of a higher risk of infection associated with hypercortisolemia. Therefore, early detection and appropriate treatment for this syndrome is necessary. But the diagnosis is challenging and the source of ACTH production can be difficult to identify. We report a 69-year-old male patient who had severe hypokalemia, metabolic alkalosis, and hypertension as manifestations of an ACTH-secreting small cell carcinoma of the lung. He was treated with ketoconazole and spironolactone to control the ACTH dependent Cushing syndrome. He survived for 15 months after chemotherapy, which is unusual considering the poor outcome of the ectopic ATH syndrome associated with SCLC.